Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...
Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in in women's health innovation.
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Traditional approaches to benchmarking brand performance have struggled to keep pace with industry dynamics. While individual ...
In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.
Dr. Dina Radenkovic, CEO of Gameto, identifies strategies to close the gap in women's health and how we can better incentivize research and development in this area.
John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback